GoldBamboo.com - Knowledge is strong medicine
  

Avicena Completes Dose-Escalation Portion Of Chronic Toxicology Study Of Parkinson's Disease Drug Candidate PD-02 - News


  Not Signed In - Sign In / Register


Get Your Free Credit Report Right Now!

Zip Code:



General Topics A-Z

Avicena Completes Dose-Escalation Portion Of Chronic Toxicology Study Of Parkinson's Disease Drug Candidate PD-02

Tue, 06 Feb 2007 08:00 AM EST

... Avicena Group, Inc. (OTC Bulletin Board: AVGO), a biotechnology company focused on commercializing its proprietary cellular energy modulation technology, announced today the completion of the dose-escalating portion of a chronic toxicology study of PD- 02, its lead Parkinson's disease drug candidate. [click link for full article] ...

Related Topics

Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $30 a year, a savings of 70% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

GoldBambooTM

Your Integrative Health and Wellness Resource

November 22, 2009


Page Updated: January 17, 2009
============== Advertisement ==============
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Health Forums

Copyright © 2004-2009 - Anaconda Partners LLC - All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.